TLIS News and Press, Talis Biomedical Corporation From 03/18/21

MENLO PARK, Calif., March 18, 2021 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (Nasdaq: TLIS), a company dedicated to developing innovative molecular diagnostic tests for infectious diseases at the point-of-care, today announced the appointment of Jeryl “Jeri” Hillema...

Bank of America has initiated the coverage on Talis Biomedical ([[TLIS]] +0.4%) with a neutral rating and a price target of $14.00 per share indicating ~8.9% upside to the previous close.The analyst Derik de Bruin sees a pandemic-driven surge in demand for tests targeting infectious diseases ...

Gainers: Second Sight Medical Products (EYES) +92%, OpGen (OPGN) +79%, Anchiano Therapeutics (ANCN) +64%, Jaguar Health (JAGX) +29%, Idera Pharmaceuticals (IDRA) +22%.Losers: Soleno Therapeutics (SLNO) -44%, AnaptysBio (ANAB) -34%, T...

MENLO PARK, Calif., March 08, 2021 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (Nasdaq: TLIS), a company dedicated to developing innovative molecular diagnostic tests for infectious diseases at the point-of-care, today announced that it has withdrawn its current applicatio...

MENLO PARK, Calif., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (Nasdaq: TLIS), a company dedicated to developing innovative molecular diagnostic tests for infectious diseases at the point-of-care, today announced the closing of its previously announced initial public off...